Reston, VA (May 4, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Wearable Brain PET Enables Real-Time Imaging Beyond the Lab
A new wearable brain imaging system, SmartBrain, captures brain activity without requiring patients to remain still. Using advanced detectors, it produced high-resolution images in lab tests, models, animal studies, and an initial human scan, demonstrating strong performance across key imaging benchmarks.
Dual-Tracer PET Scans Help Predict Survival in Liver Cancer
Researchers tested two imaging tracers before and after one month of sorafenib therapy in advanced liver cancer patients. By measuring tumor metabolism and size, they identified imaging markers—especially from standard glucose-based scans—that were strongly linked to one-year survival outcomes.
New PET Tracer Tracks Prostate Cancer Spread with Precision
Scientists evaluated a novel PET imaging tracer targeting prostatic acid phosphatase in patients with advanced prostate cancer. The tracer showed rising uptake in tumors over time, clear contrast against healthy tissue, predictable body distribution, and a relatively low radiation dose in early human imaging tests.
Kidney Function Impact of Targeted Prostate Cancer Therapy Assessed
A large registry study examined kidney function in prostate cancer patients receiving 177Lu-PSMA-617. Tracking changes over two years, researchers found a small, gradual decline in kidney performance, with higher cumulative treatment doses linked to slightly faster reductions.
Visit the JNM website for the latest research and follow our new Twitter and Facebook
